Metabolic•GLP-1 Agonist

⚖️Semaglutide

GLP-1 receptor agonist. FDA-approved (Ozempic/Wegovy). Up to 15% weight loss in Phase III trials. Reduces cardiovascular events (SELECT trial). The benchmark for GLP-1 weight loss research.

Amino acids

Mol. weight

4113.6 Da

Half-life

~7 days

Availability

On inquiry

Amino acid sequence

GLP-1 analogue with C18 fatty diacid chain

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. FDA-approved as Ozempic (T2D) and Wegovy (obesity). Its C18 fatty diacid chain enables albumin binding, extending half-life to ~7 days for weekly dosing. The SELECT cardiovascular outcomes trial (2023) demonstrated 20% reduction in MACE events in non-diabetic obese adults.

Key Mechanisms

GLP-1R agonism — hypothalamic appetite suppression (NPY/AgRP inhibition)
Gastric emptying delay — prolonged satiety duration
Glucose-dependent insulin secretion — pancreatic β-cell activation
Cardiovascular protection — reduces inflammation, improves endothelial function

Key References

Wilding JPH et al. "Semaglutide in Adults with Overweight or Obesity." N Engl J Med, 2021;384:989–1002.
Lincoff AM et al. "Semaglutide and cardiovascular outcomes in obesity (SELECT)." N Engl J Med, 2023;389:2221–2232.

Related in Metabolic

⚖️Exercise Mimetic

MOTS-C

Mitochondria-encoded exercise mimetic peptide. Activates AMPK via AICAR, improves insulin sensitivity and drives fat oxidation — independently of insulin receptor signalling.

⚖️Phase II Champion

Retatrutide (LY3437943)

Triple GIP/GLP-1/glucagon receptor agonist. Phase II trial demonstrated 24.2% body weight reduction at 48 weeks — the highest ever recorded for a pharmacological agent.

⚖️Dual Agonist

Tirzepatide

FDA-approved dual GIP/GLP-1 receptor agonist (Mounjaro/Zepbound). Up to 22.5% weight loss in SURMOUNT-1 trial. Currently the most effective approved anti-obesity medication.